CAR-NK cell therapy FT596 ‘well tolerated’ in phase 1 trial
FT596, a CD19-directed chimeric antigen receptor (CAR) natural killer (NK) cell therapy, was well tolerated in patients with relapsed or refractory B-cell lymphoma
Cellular Therapy
Lymphoma
66th American Society of Hematology Annual Meeting & Exposition
Myeloma
News
Video Interviews
Refining progression criteria in relapsed myeloma
Jean-Sébastien Claveau, MD, of Maisonneuve-Rosemont Hospital at the University of Montreal, spoke with SOHO Insider at the 66th American Society of Hematology Annual
Cellular Therapy
Multiple Myeloma
News
Do older patients with myeloma respond as well to ide-cel as younger patients?
“[T]hese findings provide reassurance that older adults treated with ide-cel, including frail patients, experience comparable efficacy to younger patients,” the authors wrote.
Multiple Myeloma
News
Society Updates
Message from Editor-in-Chief Dr. Lonial: Advancing care amid uncertainty
May you live in interesting times…. You may have encountered this adage at some point in your life, though its origins are difficult
Myeloproliferative Neoplasms
Primary Myelofibrosis
Do driver mutations influence treatment outcomes in myelofibrosis?
The absence of cancer-related mutations 30 days after a transplant in patients with myelofibrosis might be more effective in measuring treatment response than
66th American Society of Hematology Annual Meeting & Exposition
Myeloma
Researchers call for ‘evidence-based’ driving restrictions for patients treated with CAR-T therapy
Driving restrictions for blood cancer patients undergoing chimeric antigen receptor (CAR)-T cell therapy may need reconsideration.
Leukemia
Myelodysplastic Syndromes
FDA approves imatinib oral solution to treat leukemia, other cancers
The US Food and Drug Administration (FDA) has approved imatinib (Imkeldi) oral solution to treat leukemia and other cancers. Imatinib is an advanced
Leukemia
Pathways & Perspectives with Pia Raanani, MD
Pathways & Perspectives Meet Pia Raanani, MD, head of the Institute of Hematology at the Davidoff Cancer Center, Rabin Medical Center in Israel
Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndromes
NCI’s myeloMATCH pushes the envelope in myeloid leukemia care
A new National Cancer Institute (NCI) initiative seeks to redefine the standard for personalized cancer care in acute myeloid leukemia (AML) and myelodysplastic
The Twelfth Annual Meeting of the Society of Hematologic Oncology
Video Interviews
Aspiring hem/onc fellows discuss myeloma research, SOHO Annual Meeting opportunities
Wajeeha Aiman, MD, and Muhammad Ashar Ali, MD, discuss the benefits of attending the SOHO Annual Meeting in Houston, Texas, for early-career healthcare